- Dianthus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call TranscriptMay 03, 2023
- Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call TranscriptDec 13, 2022
- Magenta Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2022
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call TranscriptMay 12, 2021
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Magenta Therapeutics, Inc. - Special Call TranscriptMay 07, 2020
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Magenta Therapeutics Inc ASH 2019 TranscriptDec 08, 2019
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. We'll continue with the next session. Good morning, everyone. I'm Paul Choi, the SMid cap Biotechnology Analyst at Goldman Sachs. And with our next session, I'm very pleased to host Magenta Therapeutics. Joining us from Magenta, we have a very -- a nice large group here, including Jason Gardner, CEO; Jason Ryan, CFO. We're also pleased to have John Davis, the CMO; and Manisha Pai from IR. As with the prior sessions during the conference, I'll provide some introductory remarks and then turn it over to Jason Gardner for some opening comments. After that, we'll go into the Q&A. And then along the way, if any investors or clients have questions, please feel free to submit them along the way via the Goldman Sachs' research portal. Alternatively, you can e-mail them to me directly and time permitting at the end, I'll try and squeeze in a question or 2, should any be submitted. Otherwise, with that, I'll turn it over to Jason Gardner for some opening comments, and then we'll go into the Q&A. Jason?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)